PRAX Praxis Precision Medicines Inc
Price (delayed)
$37.11
Market cap
$748.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.21
Enterprise value
$534.26M
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights
Highlights
The debt has declined by 45% year-on-year and by 18% since the previous quarter
PRAX's equity is up by 16% from the previous quarter
The quick ratio has soared by 103% year-on-year but it has declined by 3.8% since the previous quarter
PRAX's EPS is up by 45% year-on-year but it is down by 10% since the previous quarter
The net income has contracted by 48% YoY and by 21% from the previous quarter
Key stats
What are the main financial stats of PRAX
Market
Valuations
Earnings
Shares outstanding
20.16M
Market cap
$748.26M
Enterprise value
$534.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.55
Price to sales (P/S)
77.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.46
Revenue
$8.55M
Gross profit
$8.55M
Operating income
-$200.17M
Net income
-$182.82M
EBIT
-$182.82M
EBITDA
-$181.53M
Free cash flow
-$131.76M
Per share
Balance sheet
Liquidity
EPS
-$10.21
EPS diluted
-$10.21
Free cash flow per share
-$7.36
Book value per share
$23.9
Revenue per share
$0.48
TBVPS
$26.98
Total assets
$483.11M
Total liabilities
$37.66M
Debt
$1.37M
Equity
$445.45M
Working capital
$366.82M
Debt to equity
0
Current ratio
10.77
Quick ratio
10.45
Net debt/EBITDA
1.18
Margins
Efficiency
Dividend
EBITDA margin
-2,122.4%
Gross margin
100%
Net margin
-2,137.5%
Operating margin
-2,340.3%
Return on assets
-46%
Return on equity
-49.5%
Return on invested capital
-90.6%
Return on capital employed
-41%
Return on sales
-2,137.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRAX stock price
How has the Praxis Precision Medicines stock price performed over time
Intraday
3.46%
1 week
-2.83%
1 month
-3.86%
1 year
-33.22%
YTD
-51.78%
QTD
-2.01%
Financial performance
How have Praxis Precision Medicines's revenue and profit performed over time
Revenue
$8.55M
Gross profit
$8.55M
Operating income
-$200.17M
Net income
-$182.82M
Gross margin
100%
Net margin
-2,137.5%
PRAX's operating margin has surged by 77% since the previous quarter and by 55% year-on-year
The net margin has surged by 77% since the previous quarter and by 58% year-on-year
The operating income has dropped by 58% year-on-year and by 22% since the previous quarter
The net income has contracted by 48% YoY and by 21% from the previous quarter
Growth
What is Praxis Precision Medicines's growth rate over time
Valuation
What is Praxis Precision Medicines stock price valuation
P/E
N/A
P/B
1.55
P/S
77.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
62.46
PRAX's EPS is up by 45% year-on-year but it is down by 10% since the previous quarter
PRAX's P/B is 46% below its last 4 quarters average of 2.8 and 42% below its 5-year quarterly average of 2.6
PRAX's equity is up by 16% from the previous quarter
The price to sales (P/S) is 82% less than the last 4 quarters average of 416.1
Efficiency
How efficient is Praxis Precision Medicines business performance
PRAX's return on sales has surged by 77% since the previous quarter and by 58% year-on-year
Praxis Precision Medicines's ROE has soared by 67% YoY and by 10% from the previous quarter
Praxis Precision Medicines's ROA has soared by 60% YoY and by 9% from the previous quarter
The company's return on invested capital rose by 15% QoQ
Dividends
What is PRAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRAX.
Financial health
How did Praxis Precision Medicines financials performed over time
PRAX's total liabilities has surged by 106% year-on-year and by 12% since the previous quarter
The quick ratio has soared by 103% year-on-year but it has declined by 3.8% since the previous quarter
The debt is 100% smaller than the equity
The debt to equity has dropped by 100% year-on-year
The debt has declined by 45% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.